NMRD - ネマウラ・メディカル (Nemaura Medical Inc.) ネマウラ・メディカル

 NMRDのチャート


 NMRDの企業情報

symbol NMRD
会社名 Nemaura Medical Inc (ネマウラ・メディカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 Nemaura Medical Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering developing and commercializing specialty medical devices. The Company's focus is on the development of a continuous glucose monitoring (CGM) device which consists of a disposable patch containing a sensor and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company through its operating subsidiaries performs medical device research and manufacturing of a CGM named sugarBEAT. The sugarBEAT device is a non-invasive wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes such as glucose to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.   ネマウラ・メディカルはイギリスの医療系テクノロジ―企業。糖尿病患者向けのグルコ―スモニタリングシステム機器SugerBEATを提供。同製品は同社の特許技術である使い捨て粘着性スキンパッチ(無針無痛の非浸潤性)を使用し、継続的な血液中のブドウ糖濃度の監視を行う。本社所在地はレスタ―シャ―州ラフバラ―。   Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. Through its subsidiaries, it manufactures and commercializes continuous glucose monitoring system, named sugarBEAT. The sugarBEAT is consist of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.
本社所在地 Advanced Technology Innovation Centre Loughborough University Science_Enterprise Parks 5 Oakwood Drive Loughborough Leicestershire LE11 3QF GBR
代表者氏名 Dewan Fazlul Hoque Chowdhury Dewan Fazlul Hoque Chowdhury
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +44 1509-22-2912
設立年月日 41609
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 8人
url www.nemauramedical.com
nasdaq_url https://www.nasdaq.com/symbol/nmrd
adr_tso
EBITDA EBITDA(百万ドル) -2.23264
終値(lastsale) 2.1285
時価総額(marketcap) 436342500
時価総額 時価総額(百万ドル) 461.25000
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 456.30896
当期純利益 当期純利益(百万ドル) -2.17582
決算概要 決算概要 BRIEF: For the three months ended 30 June 2018 Nemaura Medical Inc revenues was not reported. Net loss increased 87% to $763K. Higher net loss reflects Research and development increase from $149K to $430K (expense) General and administrative increase of 28% to $342K (expense) Interest Income decrease of 8% to $9K (income). Basic Earnings per Share excluding Extraordinary Items totaled to -$0.01.

 NMRDのテクニカル分析


 NMRDのニュース

   Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®  2019/05/02 13:00:00 Benzinga
Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it will allow third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free access to SugarBEAT® CGM app data. As a result, users will be able to directly access SugarBEAT® generated glucose data through their preferred participating mobile aplications, empowering users with greater choice over when to use this data to better understand how food choices and other lifestyle factors impact glucose levels. This development is part of the Company's broader go-to-market strategy, which is being led by Dr. Fred Schaebsdau. Dr. Schaebsdau joined the Company earlier this year to advance the commercialization and business development of SugarBEAT®, building on his success with earlier CGM products at Abbott Diabetes Care and Dexcom Germany." Dr.
   Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®  2019/04/23 12:00:00 Benzinga
Loughborough, England , April 23, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®. The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,' in preparation for submission of its medical device application to the FDA for SugarBEAT®. The two studies consisted of 16 participants each, including both Type I and Type II diabetics. Participants in the first and second study ranged from ages 18-50 and 51-70, respectively. The studies were designed to ensure adequate information was captured for the diverse age groups expected to use SugarBEAT®. The objective of the two studies was to confirm that the user interface aspects of SugarBEAT® met …
   Nemaura Medical files for $250M mixed shelf  2019/03/27 20:55:04 Seeking Alpha
   Nemaura establishes SugarBEAT distribution in Middle East; shares up 4%  2019/03/12 14:42:27 Seeking Alpha
   22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers  2019/03/06 16:06:16 Seeking Alpha
   Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®  2019/05/02 13:00:00 Benzinga
Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it will allow third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free access to SugarBEAT® CGM app data. As a result, users will be able to directly access SugarBEAT® generated glucose data through their preferred participating mobile aplications, empowering users with greater choice over when to use this data to better understand how food choices and other lifestyle factors impact glucose levels. This development is part of the Company's broader go-to-market strategy, which is being led by Dr. Fred Schaebsdau. Dr. Schaebsdau joined the Company earlier this year to advance the commercialization and business development of SugarBEAT®, building on his success with earlier CGM products at Abbott Diabetes Care and Dexcom Germany." Dr.
   Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®  2019/04/23 12:00:00 Benzinga
Loughborough, England , April 23, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®. The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,' in preparation for submission of its medical device application to the FDA for SugarBEAT®. The two studies consisted of 16 participants each, including both Type I and Type II diabetics. Participants in the first and second study ranged from ages 18-50 and 51-70, respectively. The studies were designed to ensure adequate information was captured for the diverse age groups expected to use SugarBEAT®. The objective of the two studies was to confirm that the user interface aspects of SugarBEAT® met …
   Nemaura Medical files for $250M mixed shelf  2019/03/27 20:55:04 Seeking Alpha
   Nemaura establishes SugarBEAT distribution in Middle East; shares up 4%  2019/03/12 14:42:27 Seeking Alpha
   22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers  2019/03/06 16:06:16 Seeking Alpha
   Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®  2019/05/02 13:00:00 Benzinga
Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it will allow third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free access to SugarBEAT® CGM app data. As a result, users will be able to directly access SugarBEAT® generated glucose data through their preferred participating mobile aplications, empowering users with greater choice over when to use this data to better understand how food choices and other lifestyle factors impact glucose levels. This development is part of the Company's broader go-to-market strategy, which is being led by Dr. Fred Schaebsdau. Dr. Schaebsdau joined the Company earlier this year to advance the commercialization and business development of SugarBEAT®, building on his success with earlier CGM products at Abbott Diabetes Care and Dexcom Germany." Dr.
   Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®  2019/04/23 12:00:00 Benzinga
Loughborough, England , April 23, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®. The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,' in preparation for submission of its medical device application to the FDA for SugarBEAT®. The two studies consisted of 16 participants each, including both Type I and Type II diabetics. Participants in the first and second study ranged from ages 18-50 and 51-70, respectively. The studies were designed to ensure adequate information was captured for the diverse age groups expected to use SugarBEAT®. The objective of the two studies was to confirm that the user interface aspects of SugarBEAT® met …
   Nemaura Medical files for $250M mixed shelf  2019/03/27 20:55:04 Seeking Alpha
   Nemaura establishes SugarBEAT distribution in Middle East; shares up 4%  2019/03/12 14:42:27 Seeking Alpha
   22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers  2019/03/06 16:06:16 Seeking Alpha

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 ネマウラ・メディカル NMRD Nemaura Medical Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)